Literature DB >> 30302042

Race and Gradient Difference Are Associated with Increased Risk of Hepatic Encephalopathy Hospital Admission After Transjugular Intrahepatic Portosystemic Shunt Placement.

Michael W Rowley1,2, Myunghan Choi3, Steve Chen4,2, Kevin Hirsch4,2, Anil B Seetharam5,2.   

Abstract

BACKGROUND/AIMS: Hepatic encephalopathy (HE) is a well-recognized complication of transjugular intrahepatic portosystemic shunt (TIPS) placement. The aim of this investigation was to evaluate incidence and predictors of post-TIPS HE necessitating hospital admission in a non-clinical trial setting.
METHODS: We performed a retrospective cohort study identifying 273 consecutive patients undergoing TIPS from 2010 to 2015 for any indication; 210 met inclusion/exclusion criteria. The primary endpoint was incidence of post-TIPS HE defined as encephalopathy with no other identifiable cause requiring hospitalization within 90 days of TIPS. Clinical demographics and procedural variables were collected and analyzed to determine predictors of readmission for post-TIPS HE. Categorical variables were analyzed using Fisher's exact test; continuous variables were compared using Levene's t-test and student's t-test; P < 0.05, significant.
RESULTS: Forty-two of 210 patients (20%) developed post-TIPS HE requiring hospitalization within 90 days. On analysis of cohorts (post-TIPS HE vs. no post-TIPS HE): non-white race (31.0% vs. 17.5%, P = 0.022) and increased hepatic venous pressure gradient (HVPG) difference during TIPS (10.5 vs. 8.9 mmHg, P = 0.030) were associated with an increased incidence of HE requiring readmission within 90 days.
CONCLUSIONS: HE remains a common complication of TIPS. Non-Caucasian race is a significant clinical demographic associated with increased risk for readmission. Independent of initial or final HVPG, HVPG difference appears to be a significant modifiable technical risk factor. In the absence of clear preventative strategies for post-TIPS encephalopathy, non-Caucasians with HVPG reductions >9 mmHg may require targeted follow up evaluation to prevent hospital readmission.

Entities:  

Keywords:  HE, hepatic encephalopathy; HVPG, hepatic venous pressure gradient; HVWP, hepatic venous wedge pressure; PTFE, polytetrafluoroethylene; PVT, portal vein thrombus; TIPS; TIPS, transjugular intrahepatic portosystemic shunt; hepatic encephalopathy; transjugular intrahepatic portosystemic shunt

Year:  2017        PMID: 30302042      PMCID: PMC6175770          DOI: 10.1016/j.jceh.2017.12.003

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  27 in total

1.  Reporting standards for transjugular intrahepatic portosystemic shunts.

Authors:  Ziv J Haskal; Chet R Rees; Ernest J Ring; Richard Saxon; David Sacks
Journal:  J Vasc Interv Radiol       Date:  2003-09       Impact factor: 3.464

2.  Improved clinical outcome with transjugular intrahepatic portosystemic stent-shunt utilizing polytetrafluoroethylene-covered stents.

Authors:  Dhiraj Tripathi; James Ferguson; Holly Barkell; Kim Macbeth; Hamish Ireland; Doris N Redhead; Peter C Hayes
Journal:  Eur J Gastroenterol Hepatol       Date:  2006-03       Impact factor: 2.566

3.  Clearing the Confusion over Hepatic Encephalopathy After TIPS Creation: Incidence, Prognostic Factors, and Clinical Outcomes.

Authors:  Leigh C Casadaban; Ahmad Parvinian; Jeet Minocha; Janesh Lakhoo; Christopher W Grant; Charles E Ray; M Grace Knuttinen; James T Bui; Ron C Gaba
Journal:  Dig Dis Sci       Date:  2014-10-15       Impact factor: 3.199

4.  Early use of TIPS in patients with cirrhosis and variceal bleeding.

Authors:  Juan Carlos García-Pagán; Karel Caca; Christophe Bureau; Wim Laleman; Beate Appenrodt; Angelo Luca; Juan G Abraldes; Frederik Nevens; Jean Pierre Vinel; Joachim Mössner; Jaime Bosch
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

5.  Ethnic differences in presentation and severity of alcoholic liver disease.

Authors:  Robert Levy; Andreea M Catana; Blythe Durbin-Johnson; Charles H Halsted; Valentina Medici
Journal:  Alcohol Clin Exp Res       Date:  2015-02-20       Impact factor: 3.455

6.  Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study.

Authors:  A J Sanyal; A M Freedman; M L Shiffman; P P Purdum; V A Luketic; A K Cheatham
Journal:  Hepatology       Date:  1994-07       Impact factor: 17.425

7.  Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study.

Authors:  Christophe Bureau; Juan Carlos Garcia Pagan; Gilles Pomier Layrargues; Sophie Metivier; Pablo Bellot; Pierre Perreault; Philippe Otal; Juan-G Abraldes; Jean Marie Peron; Hervé Rousseau; Jaume Bosch; Jean Pierre Vinel
Journal:  Liver Int       Date:  2007-08       Impact factor: 5.828

8.  Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study.

Authors:  Juan Carlos Garcia-Pagán; Marco Di Pascoli; Karel Caca; Wim Laleman; Cristophe Bureau; Beate Appenrodt; Angelo Luca; Alexander Zipprich; Juan G Abraldes; Frederik Nevens; Jean Pierre Vinel; Tilman Sauerbruch; Jaime Bosch
Journal:  J Hepatol       Date:  2012-08-30       Impact factor: 25.083

9.  Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors.

Authors:  O Riggio; M Merlli; G Pedretti; R Servi; P Meddi; R Lionetti; P Rossi; M Bezzi; F Salvatori; U Ugolotti; F Fiaccadori; L Capocaccia
Journal:  Dig Dis Sci       Date:  1996-03       Impact factor: 3.199

10.  Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with recurrent variceal hemorrhage.

Authors:  Popovič Peter; Zore Andrej; Surlan Popovič Katarina; Garbajs Manca; Skok Pavel
Journal:  Gastroenterol Res Pract       Date:  2013-03-28       Impact factor: 2.260

View more
  1 in total

1.  Readmission after TIPS: an up-to-date landscape.

Authors:  Octavi Basssegoda; Andres Cardenas
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-11-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.